Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
The four Janus kinase (JAK) proteins and seven signal transducer and activator of
transcription (STAT) transcription factors mediate intracellular signal transduction …
transcription (STAT) transcription factors mediate intracellular signal transduction …
[HTML][HTML] Natural history of COVID-19 and current knowledge on treatment therapeutic options
WG Dos Santos - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Despite intense research there is currently no effective vaccine available against the new
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in the later 2019 …
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in the later 2019 …
Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis
SR Ytterberg, DL Bhatt, TR Mikuls… - … England Journal of …, 2022 - Mass Medical Soc
Background Increases in lipid levels and cancers with tofacitinib prompted a trial of major
adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis …
adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis …
[HTML][HTML] Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
F Cantini, L Niccoli, D Matarrese, E Nicastri… - The Journal of …, 2020 - ncbi.nlm.nih.gov
As discussed in the Journal recently1 the SARS-CoV-2, a new β-Coronavirus, uses the
Angiotensin Converting Enzyme-2 Receptor to enter airway cells. Viral endocytosis is …
Angiotensin Converting Enzyme-2 Receptor to enter airway cells. Viral endocytosis is …
Baricitinib restrains the immune dysregulation in patients with severe COVID-19
BACKGROUND Patients with coronavirus disease 2019 (COVID-19) develop pneumonia
generally associated with lymphopenia and a severe inflammatory response due to …
generally associated with lymphopenia and a severe inflammatory response due to …
Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series
V Furer, D Zisman, A Kibari, D Rimar, Y Paran… - …, 2021 - academic.oup.com
Objectives As global vaccination campaigns against COVID-19 disease commence, vaccine
safety needs to be closely assessed. The safety profile of mRNA-based vaccines in patients …
safety needs to be closely assessed. The safety profile of mRNA-based vaccines in patients …
Two years into the COVID-19 pandemic: lessons learned
SJR da Silva, JCF do Nascimento… - ACS infectious …, 2022 - ACS Publications
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …
Abrocitinib versus placebo or dupilumab for atopic dermatitis
T Bieber, EL Simpson, JI Silverberg… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces
interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic …
interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic …
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …
Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19
W Luo, YX Li, LJ Jiang, Q Chen, T Wang… - Trends in pharmacological …, 2020 - cell.com
Recent advances in the pathophysiologic understanding of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …